Oramorph (Morphine Sulfate)

Morphine Sulfate, the active ingredient in Oramorph, is an opioid analgesic presented as a strength/form for oral use. It is used to treat moderate to severe pain in adult patients when other analgesics are insufficient. GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oramorph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oramorph is an opioid analgesic that acts within the central nervous system to relieve pain.

- Acute postoperative pain: provides effective relief following surgical procedures. - Cancer‑related pain: helps manage moderate to severe pain associated with malignant disease. - Chronic non‑cancer pain: used when long‑term opioid therapy is deemed appropriate by a clinician. - Severe traumatic injury pain: reduces pain intensity after major injuries. - Palliative care pain: improves comfort in end‑of‑life settings.

Side effects vary with dose, duration of therapy and individual sensitivity.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea and vomiting: stimulation of the chemoreceptor trigger zone. - Drowsiness: central nervous system depression. - Dry mouth: decreased salivary secretion. - Sweating: autonomic activation. - Itching: histamine release.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Opioid dependence or withdrawal syndrome. - Adrenal insufficiency: impaired cortisol production. - Severe allergic reaction: anaphylaxis or angioedema. - Neurotoxicity: seizures or altered mental status.

When prescribing Oramorph, clinicians should consider patient‑specific factors and follow safe‑use guidelines.

- Assess pain severity and prior opioid exposure: ensure opioid therapy is appropriate. - Evaluate respiratory function: monitor for depression, especially in opioid‑naïve patients. - Review concomitant CNS depressants: adjust dose or increase monitoring. - Screen for substance‑use disorder: consider risk‑mitigation strategies. - Adjust dose in renal or hepatic impairment: use the lowest effective dose. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Morphine sulfate may interact with several medication classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: combined CNS depression can cause profound respiratory depression. - Barbiturates: additive sedative effects increase risk of fatal overdose. - Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Anticholinergics: may worsen constipation. - Diuretics: can enhance hypotensive effects. - Certain antidepressants (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome. - CYP3A4 inhibitors (e.g., ketoconazole): may raise morphine plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce morphine effectiveness.